Last reviewed · How we verify
SPK-9001
At a glance
| Generic name | SPK-9001 |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B (PHASE2)
- A Gene Therapy Study for Hemophilia B (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPK-9001 CI brief — competitive landscape report
- SPK-9001 updates RSS · CI watch RSS
- Pfizer portfolio CI